CytoMed Therapeutics Limited (GDTC) Options Greeks

Options Greeks measure sensitivity to various factors: Delta (price), Gamma (delta change), Theta (time decay), and Vega (volatility). They are essential for risk management and position sizing.

CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $12.1M, listed on NASDAQ, employing roughly 42 people, carrying a beta of 0.02 to the broader market. CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. Led by Chee Kong Choo, public since 2023-04-14.

Options Greeks analysis provides sensitivity measures for price, time, and volatility. No recent options activity for GDTC as of 2026-07-17; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how options Greeks is reported and how to read the data →